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Abstract HIV infection has become a chronic illness when
successfully treated with combined antiretroviral therapy
(cART). The long-term health prognosis of aging with con-
trolled HIV infection and HIV-associated neurocognitive
disorder (HAND) remains unclear. In this review, we propose
that, almost 20 years after the introduction of cART, a change
in research focus is needed, with a greater emphasis on
chronicity effects driving our research strategy.We argue that
pre-emptive documentation of episodes of mild neurocogni-
tive dysfunction is needed to determine their long-term
prognosis. This strategy would also seek to optimally repre-
sent the entire HAND spectrum in therapeutic trials to assess
positive and/or negative treatment effects on brain functions.
In the first part of the paper, to improve the standard imple-
mentation of the Frascati HAND diagnostic criteria, we pro-
vide a brief review of relevant quantitative neuropsychology
concepts to clarify their appropriate application for a non-
neuropsychological audience working in HIV research and
wanting to conduct randomized clinical trials on brain func-
tions. The second part comprises a review of various
antiretroviral drug classes and individual agents with respect
to their effects on HAND, while also addressing the question
of when cART should be initiated to potentially reduce
HAND incidence. In each section,weuse recent observational
studies and randomized controlled trials to illustrate our per-
spective while also providing relevant statistical comments.
We conclude with a discussion of the neuroimaging methods
that could be combined with neuropsychological approaches
to enhance the validity of HIV neurology (neuroHIV) treat-
ment effect studies.
Key Points
HIV infection has become a chronic illness when
successfully treated with combined antiretroviral
therapy (cART). The long-term health prognosis of
aging with controlled HIV infection and HIV-
associated neurocognitive disorder (HAND) remains
unclear.
With a research focus on chronicity, pre-emptive
documentation of episodes of mild neurocognitive
dysfunction is needed to determine their long-term
prognosis. This strategy would also seek to optimally
represent the entire HAND spectrum in therapeutic
trials to assess positive and/or negative treatment
effects on brain functions.
No individual agent or group of antiretrovirals has
unequivocally showed benefits for treating or
preventing HAND in the cART era, but there are
promising results, which we critically review in light
of the increasing importance of chronicity effects.
Prospective randomized clinical trials should be the
preferred approach for HIV neurology (neuroHIV)
treatment studies, including optimized adaptive
randomization approaches to balance HAND clinical
categories in treatment arms.
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1 Introduction
HIV infection has become a chronic illness when suc-
cessfully treated with combined antiretroviral therapy
(cART). The long-term health prognosis of aging with
controlled HIV infection remains unclear especially in
regard to HIV-associated neurocognitive disorder (HAND).
Research on normal aging indicates that our under-
standing of neurocognitive functioning is best informed
through life-span studies [1]. The same analytic framework
is required when investigating chronic diseases, which by
their nature interact with the aging process. Studies based
on large samples and using longitudinal analyses are sorely
lacking in HIV neurology (neuroHIV) research, leaving us
with an incomplete understanding of the long-term course
of HAND in the era of chronic HIV infection [2]. Fur-
thermore, there are several factors unique to neuroHIV that
need to be carefully considered alongside normal aging
effects. Firstly, the clinical profile of HAND has changed
with the introduction of cART, such that the majority of
HIV-infected [HIV-positive (HIV?)] persons do not
develop HIV-associated dementia (HAD), but rather a
milder form of the disease detectable on standard neu-
ropsychological testing. Secondly, current longitudinal
cohorts investigating the effects of chronic HIV and/or
aging are systematically biased by a survivor effect where
most individuals who developed HAD in the pre-cART era
have died. The survivor bias also ‘‘excludes’’ those who
have died of other AIDS causes and may have developed
HAD as they aged. The size of this effect cannot be
quantified easily, especially when considering protective
factors (e.g., cognitive resilience or resistance to the effects
of aging on the brain) that could explain the comparatively
low HAD incidence in more recently studied cohorts.
Thirdly, prospective data in large samples (N[ 1000) on
the effect of HIV chronicity on brain functions are cur-
rently lacking at an international level, especially those
focusing on HIV? persons who received cART as a first-
line treatment (rather than any pre-cART regimen).
Moreover, in many countries these people are still fairly
young (\50 years old), meaning that we are not yet at a
stage where research on aging and HIV chronicity effects
can begin in earnest. Nevertheless, it is important to start
working towards a consensus on the best strategies for
documenting HAND over the life span of HIV infection
and how these data could in turn inform treatment guide-
lines for HAND.
In this review we suggest that, almost 20 years after the
initial introduction of cART in 1996, a change in research
focus is needed, with a greater emphasis on chronicity
effects driving our research strategy, echoing the view-
points of other experts in the field [3]. For this to succeed,
we argue that pre-emptive documentation of episodes of
mild neurocognitive dysfunction is needed to determine
their long-term prognosis. This strategy would also seek to
optimally represent the entire HAND spectrum in thera-
peutic trials to assess positive and/or negative treatment
effects on brain functions.
Our perspective on this issue is informed by neurocog-
nitive research in large prospective cohorts of aging and
non-HIV dementia showing that pathological brain pro-
cesses precede any symptoms by 20–30 years, and that
disease expression varies depending on complex relations
between age, cognitive/brain reserve, genotype and
pathological burden [4, 5]. While the neurodegenerative
causes of neurological deficits are different from the viral
causes, the chronicity of HIV infection is a ‘‘game chan-
ger’’ [6]. Notably, it can be expected that with improved
survival rates in the HIV population today, neurodegener-
ative pathology and low-grade neuroinflammation docu-
mented in chronic HIV infection will have time to
accumulate in some patients [7]. Our perspective is also
anchored in several key concepts of modern quantitative
neuropsychology, the most important being that optimal
assessment and definition of the baseline level of neu-
rocognitive functioning is essential in order to reliably
quantify neurocognitive change, and in turn the longer-
term prognosis [8]. Finally, when considered together,
these two propositions indicate that sampling for neuroHIV
clinical trials will need to include patients falling along the
entire HAND spectrum to optimally detect positive and/or
negative treatment effects.
2 Clarifying Quantitative Neuropsychology
Concepts
Because HIV treatment effect studies are in essence lon-
gitudinal, what is relevant for neuropsychological obser-
vational prospective studies is also relevant for randomized
controlled trials (RCTs) of HIV treatment on brain
functions.
In recent years, several neuroHIV researchers have
begun to question the validity of the milder forms of
HAND, which in the context of the Frascati criteria is
indicated by the nomenclatures asymptomatic neurocog-
nitive impairment (ANI) or mild neurocognitive disorder
(MND) when functional decline is evident [9–11]. This
debate is important because it indirectly impacts on whe-
ther such patients should be included in treatment studies.
Questioning the existence of mild forms of neurocognitive
impairment is understandable, especially in terms of the
immediate clinical relevance and the issue of whether or
not to inform patients [11]. However, psychometric,
quantitative and clinical neuropsychology concepts should
not be truncated in the process. In this section, we will
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therefore clarify some of those concepts and highlight the
importance of their correct scientific definition and
implementation, which can be used in designing neuroHIV
RCTs. Moreover, we will highlight how mild HAND
should be ‘‘re-conceptualized’’ in the context of chronic
HIV infection and argue that we should focus on the long-
term prognosis of such deficits rather than be primarily
concerned with debates over their immediate clinical
significance.
2.1 Test, Individual Neuropsychological Measure
and Cognitive Domain
A neuropsychological test simply refers to the name or
legal appellation of a test (e.g., Trail Making Test; TMT); a
neuropsychological measure denotes the (often multiple)
relevant outcome measures of a test (e.g., TMTA time to
completion; TMTB time to completion); and a cognitive
domain is an umbrella term for a set of related neuropsy-
chological measure(s) (but not tests) that are combined on
the basis of their unique correlation structure to form an
independent cognitive construct, based on factorial analytic
studies [12] yielding a model of normal cognitive func-
tioning (e.g., TMTA primarily assesses speed of informa-
tion processing, psychomotor speed and visual scanning;
TMTB also assesses these skills along with aspects of
executive functioning and working memory). The termi-
nology confusion is unfortunately present in the Frascati
criteria, which only refers to ‘‘tests’’ [13]. This has led to
the criteria being wrongly applied in several studies,
especially where more than one single neuropsychological
measure (not test) is used per cognitive domain. Incorrect
application of the HAND criteria has produced extravagant
rates of low performance in HIV-negative (HIV-) control
samples and neurocognitive impairment in HIV? samples
[14], and some have concluded that the Frascati criteria
fundamentally ‘‘over-diagnose HAND’’.
2.2 Implementation of the Frascati Criteria Using
Z-Score Domains
The optimal implementation of the Frascati criteria as
delineated in Antinori et al. [13] is dependent on three
conditions: (i) a fairly large battery size (at least ten
measures; 15 measures and five cognitive domains are
recommended at the very minimum); (ii) the use of
demographically corrected scores (e.g., age, gender, edu-
cation, ethnicity), which we will define below; and (iii) the
rating of impairment in cognitive domains as delineated in
Woods et al. [15]. This paper explains the correct process
for rating impairment when a cognitive domain is com-
posed of one or more neuropsychological measures.
However, this publication is based on demographically
corrected T-scores and deficit scores, which are less com-
monly used by non-neuropsychologists. We have therefore
provided their correct computation using more widely used
z-scores in Table 1. While we provide this to improve the
standardization of neuropsychological domain rating in
HIV infection and implementation of the Frascati criteria,
we urge research teams to involve neuropsychologists in
the early stages of study planning to avoid computational
or conceptual errors between different types of standard
scores and impairment rating methods.
2.3 Normal and Impaired Performance in Clinical
Versus Normal Samples
Normative data are sometimes seen as a uniquely neu-
ropsychological problem. However, all types of brain
measurements (including biomarkers) are sensitive to non-
disease effects, and in particular demographic effects. This
issue requires particular consideration in neuropsychology
as individual neuropsychological measures (typically
administered as part of a test battery) have unique and
complex relationships with demographic variables; for
example, some have non-linear relationships with brain
functions, while others are contextual in nature (e.g., socio-
historical effects of ethnicity). The picture is further com-
plicated by the high degree of inter-relatedness amongst
demographic variables (e.g., ethnicity or geographical
location is sometimes a proxy variable for more direct
effects of education and socioeconomic status [16]).
However, this is first and foremost a reflection of the
brain’s complexity. ‘‘Good normative data,’’ that is, data-
sets based on a large sample size with well-identified
demographic effects broadly representative of a group of
people (usually a nation) for each neuropsychological
measure is seen as a luxury because it is resource intensive.
On the contrary, this approach is in fact less costly at a
national level than many other scientific methods because
benefits are cross-disciplinary. Importantly, acquisition of
neuropsychological data in a healthy control group does
not in and of itself constitute ‘‘good’’ normative data per
se. Accurate quantification of demographic and/or socio-
cultural effects is critical for an optimal norming process.
Large samples are necessary to stabilize demographic and
other effects relevant to normal performance. This is cru-
cial both for ensuring representativeness (typically at a
national level) and stabilizing inter-correlation within a test
battery so that the factor loadings reflecting ‘‘normal’’
functioning across cognitive domains can be approximated
as closely as possible. This is not to say that small- to
medium-sized samples (N = 50–100) of HIV- persons
cannot be used as a normative reference in HIV research;
however, there are important conditions and limitations to
their use. Indeed, if the Frascati criteria are to be applied
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optimally, then they should only be used in relation to a
restricted and closely comparable HIV? sample (prefer-
ably of similar size and, as a bare minimum, comparable
for age and sex) [17]. To illustrate some of the issues
associated with using a small HIV- control sample to
assess the validity of the Frascati criteria, we specifically
review a recent study by Meyer et al. [10], which analyzed
the false-positive rates arising from different computations
of the criteria in a Kenyan HIV- sample (N = 84) as well
as a simulation sample. The demographic characteristics of
the Kenyan sample were not presented including key
variables that we know dramatically influence the stability
of normal neuropsychological performance in limited-re-
source settings [18, 19]. The study also does not report if
the tests were culturally adapted for the Kenyan sample,
which makes it even harder to determine if uncontrolled
socio-demographic effects have affected their performance.
Under such circumstances the construct validity of a neu-
ropsychological battery can be substantially reduced,
resulting in a given test measuring construct(s) other that
the cognitive function(s) that it is intended to measure. In
this instance, some of the explanatory variance due to
demographic factors is likely interfering with the test
construct, meaning that in the context of correctly applying
the Frascati criteria, the HIV- sample can only be utilized
if compared with a closely matched HIV? sample, as the
criteria assumes that test constructs will be similar for both
samples. As further support for their arguments, the criteria
were also tested in a somewhat vaguely defined simulated
normal sample. However, their computations assumed
configurations and correlational structures amongst the test
battery that generally fail to reflect the neuropsychology
methods advocated in the Frascati criteria, and as such their
conclusions serve only to reiterate existing psychometric
knowledge gleaned from Classical Test Theory [20]. Even
when the CNS HIV Anti-Retroviral Therapy Effects
Research (CHARTER) study test battery was considered,
at no time did the authors correctly compute the Frascati
criteria, as they failed to take into account the neuropsy-
chological measure/domain count specific to this test bat-
tery [21]. Their proposition to apply a cut-off at -1.5 SD/
cognitive domain is in fact already in use if at least two
neuropsychological measures are included in a cognitive
domain, as detailed above. It would be interesting, how-
ever, if the simulation work was re-conducted after cor-
rectly applying the Frascati criteria, and possibly using the
Global Deficit Score (GDS) method as they suggest (also
see the later section on updating the Frascati criteria).
Strictly speaking, normative data include demographic
corrections that have been carefully identified in the
norming process [16]. This can be achieved using one of
two approaches. One is to develop z-scores stratified by age
and education ranges (and sometimes sex). This strategy is
used by most test developers in samples that are rarely
N[ 300, except for some major test batteries [16]. The
application of such z-scores is restricted to clinical samples
with closely comparable demographics, as explained above
[16]. A second, more sophisticated method is to create
demographically corrected T-scores (another type of stan-
dard score), which represent a predicted value that is cor-
rected for demographic effects using linear and non-linear
analyses [22]. This method has been used in large samples
(N[ 1000) [22]. Importantly, this method actually elimi-
nates demographic effects, while demographically stratified
z-scores do not. This means that demographically corrected
T-scores provide the closest approximation to the individ-
ual’s personal circumstances and therefore produce themost
accurate disease-related effect. Performance in large nor-
mative datasets is typically distributed according to the
Normal curve, especially when averaged across several
neuropsychological measures (as in a cognitive domain).
Performance at the lower tail of the distribution can be
defined as impaired according to statistical criteria. In other
words, in a non-clinical sample, this level of performance is
not abnormal per se, but represents lower normal perfor-
mance. As such, equating impaired performance in clinical
and normal groups is not correct (another concept that was
not operationalized correctly in the Meyer et al. study [10]).
This is especially true when using demographically cor-
rected T-scores because the level of impairment is primarily
a reflection of a disease effect in the clinical sample.
Importantly, because an increasing number of RCTs
addressing prevention and treatment of HAND are likely to
be conducted in low- and middle-income settings, funding
for the establishment of normative data in these countries
will be needed.
Table 1 Correct Frascati cut-offs for cognitive domains defined by one, two and three individual neuropsychological measures
Neuropsychological measures in domain 1 2 3
Primary cut-off for domain impairment \-1 SD \-1 SD on both measures
OR
\-1.5 SD on at least 1 measure
\-1 SD on at least 2 measures
OR
\-1.5 SD on at least 1 measure
Note that we use\ and not B. This cut-off is recommended to start to define impairment from -1.1 Standard Deviation (SD)
Note also that the memory domain when included is defined as impaired only if there is evidence of a retention deficit (see Woods et al. [15] for
more details)
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2.4 Sensitivity and Specificity to HAND, Cut-Offs
and Battery Size
Sensitivity and specificity to brain-related disease effects
on neuropsychological functions are bound together in an
inverse relation. Therefore, to detect a mild level of clinical
impairment, as in the case of milder HAND, an *15 %
cut-off of false positives has been proposed [13] (N.B.,
based on a fairly large battery of at least five cognitive
domains and using demographically corrected T-scores).
This cut-off yields the best compromise between specificity
and sensitivity to HIV-related brain injury [23], and this is
the central argument for its existence. Proposing to modify
the trade-off by reducing the false positives rate close to
zero [10] will systematically result in an almost total loss of
sensitivity to mild neurocognitive deficits in HIV? sam-
ples. Considering what we have explained above, namely
that the false-positive rate in an HIV- sample is not the
exact equivalent of a clinical sample, especially if demo-
graphic corrections have been applied, then it happens that
the expected level of low normal performance in a clinical
sample (the ‘‘actual’’ false positives) using Frascati criteria
is really closer to 5 % than 15 %, something that was not
adequately represented in Meyer et al. [10]. To further
illustrate this point, we will use some of our Australian
HIV- sample (N = 49) neuropsychological data (based on
seven cognitive domains and 11 neuropsychological mea-
sures), reported in Cysique et al. [17]. This sample was
closely comparable to the HIV? sample (N = 90) in terms
of standard demographic and lifestyle factors, indicating
that despite the small sample sizes, the Frascati criteria can
be applied in this context. We determined rates of the
mildest level of impairment, requiring two impaired
domains according to the following definition: if the cog-
nitive domain is composed of one measure, \-1
SD = domain impaired; if the cognitive domain is com-
posed of two measures,\-1 SD in measures 1 and 2. In
our analysis, 15.5 % met this cut-off in the HIV? group
and 14.3 % in the HIV- group. However, on closer
inspection, only 6/90 (6.6 %) HIV? participants showed
impairment in two domains between -1 and -1.5 SD. All
other cases exhibited lower performance, indicating that
only *5 % of cases represent a non-clinically meaningful
level of deficit. As we will outline further below, we rec-
ommend these cases be followed up as some of them may
be on the path to decline [24–26].
Meyer et al. [10] also propose to reduce the range of
neurocognitive functions assessed at baseline for HAND
diagnosis. HAND is a fundamentally evolving disease [27]
due to cART impact, and subtle changes in neuropsycho-
logical profiles have been noted between the pre-cART and
cART eras [28, 29]. These changes may become even more
pronounced when HIV? persons reach their 70 s, an age at
which neurodegenerative processes often translate into
neurobehavioral symptoms. Reducing the number of cog-
nitive abilities assessed carries the risk of ‘‘missing the
target,’’ particularly in HIV? aging persons. If applied to
the Frascati criteria, these decisions could have far reach-
ing consequences for neuroHIV research in general, for all
HIV? patients, especially as they age, as well as for
treatment studies. Finally, what would be the consequences
of artificially reducing our capacity to detect mild impair-
ment in the context of chronic treated HIV infection?
Given the causes and prognosis of HAND are mostly
unknown, the validity of biomarkers and neuroimaging
studies would be reduced. The majority of HAND cases in
cART-treated cohorts (50–70 %) [17, 21] would also be
excluded from RCTs, including a proportion of MND cases
if functional impact has not been evaluated in detail [30].
Again, we believe that these cases should be correctly
characterized clinically and statistically using the Frascati
criteria and included in longitudinal studies for monitoring
and/or RCTs for evaluation of treatment effects.
2.5 Mild to Moderate Global Neurocognitive
Impairment Does Not Constitute a Negligible
Deficit
This argument has been historically demonstrated for var-
ious neurological and psychiatric disorders that are diag-
nosed on the basis of the assessment of neurocognitive
functions, and is therefore not specific to HIV [31]. Evi-
dence in non-HIV populations show that such levels of
neurocognitive deficit, sometimes on a single neuropsy-
chological measure, are predictive of later deterioration
[32]. Furthermore, it is well recognized that neuropatho-
logical changes preceding the onset of elderly dementia
occur decades ahead and build up slowly over time [5].
Similar mechanisms can be expected in chronic HIV/
HAND. More specifically, a history of compromised
immunity (if cART was initiated late), and low-grade
chronic HIV-related neuroinflammation (that can be pre-
sent despite cART) are both likely to affect the trajectory to
neurodegeneration, especially in those with general
dementia genetic risk [33, 34]. This means that global mild
to moderate levels of neurocognitive impairment may
represent ‘‘the tip of the iceberg’’ in some patients com-
pared to what is happening in the brain, especially if
compensatory mechanisms (e.g., brain/cognitive reserve,
coping strategies) are considered [35].
2.6 Confounds Versus Diseases Effects
While selecting mild to moderate levels of global neu-
rocognitive impairment as an initial cut-off for clinically
relevant impairment has advantages in detecting the earliest
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organic form of brain injury, this cut-off level can also be
sensitive (although this is not systematic [36, 37]) to other
conditions such as psychological distress, learning disabil-
ities, very low levels of education, alcohol and substance
use disorders and uncomplicated hepatitis C (N.B., an
optimal norming process will also reduce the effect of such
confounds, especially education). This has led some neu-
roHIV researchers to suggest that HIV is not driving the
neurocognitive impairment behind ANI and MND [11].
However, the reality is more complex. Based on clinical
experience and research data, HIV and confounding neu-
ropsychological factors tend to coexist in a complex man-
ner, especially in the context of chronic disease [38, 39]. In
fact, when they co-occur they more often interact and/or
converge in the same person to worsen mild neurocognitive
deficits rather than simply supplant them [40]. This is the
most typical profile seen aside from in cases of acute or very
severe neurological or psychiatric disease [41], although
such cases are usually excluded in current neuroHIV
research. In fact, recent US [21] and African [42] data in
high confound cases demonstrate very high impairment
rates ([80 %). Moreover, another complication of chronic
HIV is that HAND does not show a linear path to deterio-
ration. With chronicity, phases of relapse and remission can
be separated by years [43]. In this framework, only long-
term longitudinal research can detect a link between epi-
sodes of ANI or MND. This type of research is still in its
infancy in chronic HIV infection, and results thus far sug-
gest that ANI is indeed predictive of future deterioration in
cohorts with and without confounding neuropsychological
conditions [24–26]. Another issue is acceleration of age-
related co-morbidities in those with chronic HIV infection
(primarily cardiovascular disease, which is a known risk
factor for non-HIV dementia). Increased age-related co-
morbidity burden has the potential to alter the profile of
neurocognitive deficits in HAND either by accelerating
HIV-related neurocognitive decline or by involving new
cognitive deficits not typical of HIV-related brain injury. As
with the confounding conditions delineated above, age-re-
lated co-morbidities are also likely to interact in a complex
manner with existing HIV-related brain injury rather than
simply supplant it. It is within this context that we can
understand why arbitrarily deciding that ANI and MND
have no prognostic value by excluding them from early
detection could have damaging consequences for patients
and the research field as a whole. In RCTs, the careful
documentation of various confounds should be conducted a
priori. Excluding high confound cases is advised when
assessing HIV treatment effects, but exclusion of milder
confounds should be based on a careful rationale so as to
avoid creating totally unrepresentative groups. Finally, the
newest adaptive randomization algorithms [44] may be
used as a strategy to balance mild confounds between arms.
2.7 Early Versus Late Detection
The argument for refocusing the field on more severe forms
of HIV-related brain injury is perplexing if one considers
the history of the HAND diagnostic nomenclatures [45–
47]. All of the earliest terminologies incorporated mild to
moderate levels of deficits that were pre-dementia, and
even then, progression to dementia was not systematic,
only more frequent than it is today, so many cases could
have still been considered ANI/MND then. The Frascati
criteria provide a more robust neuropsychology framework
for their detection (see Fig. 1). The shift to early detection
of brain dysfunction has now happened in all areas of the
neurological sciences because neuroimaging, neuropatho-
logical and neurobiological data convincingly indicate that
brain damage precedes evidence of neuropsychological
deficit by decades [48]. In contrast, advocating a renewed
focus on the more demented forms of HAND [9], when we
all agree that they are now relatively rare, really misses the
point. The potential consequences of such a strategy in the
era of chronic HIV infection have not been sufficiently
communicated to the broader HIV community and
researchers wanting to lead clinical trials of ART effects on
brain functions: (i) in terms of research, reasoning that the
disease of interest is rare indirectly justifies lower funding
of this area when more is needed to understand the long-
term prognosis of such deficits; (ii) as far as patient care is
concerned, it contradicts the views expressed by patients
with mild HAND when given the opportunity to contribute
to the debate [49]; (iii) clinically, there is evidence that
with extensive and detailed assessment of everyday living,
many ANI are in fact MND [30, 50]; (iv) it contradicts an
emerging movement amongst patient advocacy groups for
better recognition and destigmatization of early forms of
cognitive impairment [51]; and (v) most relevant to our
review, it contrasts indications for early cART initia-
tion/modification, which necessitates screening, assessment
and monitoring of HAND.
2.8 Feedback to Patients
It has been stated without supportive evidence [9] that
knowing one has some level of cognitive impairment
causes distress for patients while the converse does not.
From our clinical experience, the reality is more complex.
Most patients can be categorized in one of four ways. The
first group does not have cognitive problems but like to be
screened and reassured that everything is ‘‘normal.’’ The
second group experience cognitive difficulties without
understanding why and are therefore quite distressed.
Objectification of deficits relieves some of that distress
because these patients can start to put strategies in place to
compensate for these problems [52]. These two groups
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represent the majority of patients who often participate in
research studies. A third group of patients worry about
HAND as a manifestation of an underlying co-morbid
anxiety disorder. They tend to seek regular neuropsycho-
logical examinations (including as research participants),
and are convinced ‘‘something is going on’’ despite evi-
dence of normal functioning. We advise these patients be
referred for anxiety treatment/therapy, followed up nor-
mally for their HIV disease and cognition and given con-
tinual reassurance. The fourth group does not seek
neuropsychological testing or consciously avoids it. Some
of these patients have co-morbid alcohol/substance use
disorders and/or chronic psychiatric conditions. They often
try to minimize their functional difficulties [53] and are
often lost to follow-up in research studies if they participate
at all. There is no straightforward way to engage these
patients, but it would be advisable to offer them short
screening rather than lengthy testing. Neuropsychological
feedback also needs to take into account those circum-
stances. Overall, the principal message that clinicians and
researchers need to communicate to patients is that they
may experience some degree of cognitive deficit living
with the illness; however, it is unlikely to evolve to
dementia if they remain stable on cART, and it is better to
monitor these mild difficulties similar to other co-mor-
bidities. Our failure to coherently deliver this message
produces undue anxiety in too many patients. Finally, in
the absence of clear therapeutic interventions for chronic
HAND at present, aside from suppressing HIV viral load in
the plasma and Cerebrospinal Fluid (CSF), it is highly
recommended that tailored psychological care be offered
(especially for those with a history of anxio-depressive
symptoms), similar to standard of care in other chronic
diseases (e.g., cancer) [54], and steps be taken to lower
HIV- and non-HIV-related modifiable risks of cognitive
dysfunction [55]. These kinds of preventative measures
will in fact be less costly over the long term because they
positively alter the course to deterioration [56].
2.9 An Update of the Frascati Criteria is Needed
The Frascati criteria should be updated primarily to
describe guidelines for monitoring patients’ neurocognitive
functioning in the context of chronic treated HIV infection.
More research is needed to establish such guidelines.
Indeed, the course of HIV-related mild neurocognitive
difficulties remains unclear, and expecting all patients to
conform to a single trajectory is unlikely to be correct (as
elegantly demonstrated in a recent article based on the
Multicenter AIDS Cohort Study [57]). Moreover, it is
unclear at what level of decline patients should receive
further clinical follow-up and/or undergo cART modifica-
tion. Similarly, it is unclear when patients have fully
recovered from a HAND episode. In updating the Frascati
Fig. 1 Correspondence between the 1988 ADC and The Frascati
HAND diagnostic nomenclatures. The rationale for the overlap
between the two nomenclatures is based on the evidence that cART
has decreased the clinical severity of HAND [77, 78]. cART combined
antiretroviral therapy, ANI asymptomatic neurocognitive impairment,
MND mild neurocognitive disorder, HAND HIV-associated neu-
rocognitive disorder, HAD HIV-associated dementia
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criteria, we should also (i) clarify both the correct method
of computing the criteria, as outlined above, and the trade-
offs in detecting mild forms of HAND in cross-sectional
versus longitudinal studies; and (ii) include the GDS as an
alternative computational method, as the GDS shows
strong validity in small (minimum six individual neu-
ropsychological measures) and large (greater than ten
measures) test batteries [58], although when applied in a
relatively small HIV- sample (\200), the level of ‘‘low
normal’’ performance can still be empirically validated to
reach a maximum of 15 %. [58]. This means that the GDS
cut-off of C0.50 can be slightly modified to obtain the best
compromise between sensitivity and specificity without
invalidating the Frascati criteria. The strength of the GDS
resides in ‘‘weighting the neuropsychological data in a
similar manner to clinical ratings by considering both the
number and the severity of deficits in an individual’s per-
formance throughout the test battery, giving relatively less
weight to performances within and above normal lim-
its’’[58]. Secondly, ‘‘the cutpoint is roughly equivalent to
averaging mild impairment on one-half of the component
measures’’ [58] so that the GDS is slightly more conser-
vative than the domain rating methods of the Frascati cri-
teria. However, one caution in using the GDS is that as an
average score, clinically significant impairment in one
domain could yield an overall normal GDS. While this is
unlikely to occur in chronic treated HIV infection, it may
occur in older persons with HIV infection also developing
neurodegenerative diseases. This is why we propose
maintaining both impairment definition methods as they
demonstrate excellent equivalence [58, 59], yet the com-
paratively simple computation of GDS should help to
resolve the inconsistent and divergent implementation of
the current Frascati criteria in our research field, as outlined
above.
3 Antiretrovirals, cART and Neuropsychological
Functions in HIV Infection
Current HIV neuropathogenesis models developed from
animal and autopsy data demonstrate that the trafficking of
HIV-infected peripheral monocytes to the blood–brain
barrier (BBB) where they accumulate as perivascular
macrophages plays a primary role in HIV-related brain
injury. Perivascular macrophages enter the central nervous
system (CNS) via a ‘‘Trojan horse’’ mechanism and a
major inflammatory response ensues [60]. Models of CNS
invasion were conceived in the context of primary HIV
infection when the BBB becomes increasingly porous (due
to massive HIV replication), facilitating the infiltration of
many cell types, including monocytes/macrophages, den-
dritic cells and CD4? T cells [61]. This massive HIV
seeding in brain tissue corresponds with the severity of
HAD observed in untreated HIV? persons. Reduction of
the overall trafficking once on cART could explain why we
now see mostly mild to moderate forms of HAND. But
overall, in vivo and clinically relevant human data are
needed to determine if this model is still relevant in long-
term virally suppressed HIV infection. Studies from one
group have produced findings in humans supporting the
monocytes’ pathway [62] in some virally suppressed
patients. But on careful inspection, their evidence is far
stronger in cases of HAD than milder HAND and in non-
treated or only recently virally suppressed patients, similar
to our own findings [63].
An alternative non-exclusive model of current HIV
neuropathogenesis is based on the increased HIV com-
partmentalization between the CNS and body. This model
posits that HIV could replicate only in the CNS at low level
or be associated with chronic neuroinflammation involving
mechanisms that remain to be fully elucidated. In support
of this model, CSF viral escape of HIV is more common
than previously thought in plasma virally suppressed
patients (see Ferretti et al. [64] for a recent review) and
presents distinctive env strains compared to plasma [65],
suggesting a high level of compartmentalization.
It is unclear at what level of chronic neuroinflamma-
tion/residual CNS viral replication HAND becomes neu-
ropsychologically detectable. Yet, several studies have
shown that HAND can develop and worsen despite viral
suppression in both plasma and CSF in 10–30 % of cases
[66, 67]. Furthermore, CSF and neuroimaging studies
have demonstrated continued signal of intrathecal
inflammation despite viral suppression [68–71]. CNS viral
replication may happen in part because individual ART
agents do not penetrate the BBB in sufficient concentra-
tions and/or two individual agents with good CNS pene-
tration when combined interact via complex CNS efflux
mechanisms to reduce CNS entry. There may be even
more complex mechanisms, which have recently been
reviewed [72]. Finally, BBB impairment in some patients
could still allow reasonable cART entry to the CNS, a
mechanism proposed long ago by Brew [6], but remains
to be investigated systematically in well-defined HAND
cohorts. Yet, evidence for chronic BBB impairment in
HIV infection exists [73, 74]. This means that cART
concentrations in the brains of historically and neurolog-
ically advanced patients should not be extrapolated to
well-controlled patients without any prior history of
advanced HIV-neurological disorder [75]. In other words,
clinical and HAND characteristics of a sample should
always moderate the interpretation of any RCTs exam-
ining cART and brain functions.
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4 CPE, Limitations and Future
The CNS Penetration Efficiency rank score (CPE) estab-
lished in 2008 and revised in 2010 [76] remains the focus
of observational studies more than RCTs at the time of
writing. In 2009 [77] and 2011 [78], our group published
reviews on ART and neuropsychological functions high-
lighting the need for this treatment effect to be studied in
RCTs. At the time, we also emphasized the need for suf-
ficiently powered trials and developed statistical scenarios
for different types of analyses and the required power to
assist the development of future trials. Since then, results
have been mixed, with several observational cross-sec-
tional or prospective studies finding negative or no effect of
CPE on cognitive functions or brain structural changes
[79–82], while others found positive effects on specific
neurocognitive functions and protective effects over time
on HAND incidence and deterioration [83]. Finally, others
have provided cumulative evidence that CPE is associated
with greater CSF viral reduction [84]. Controversially,
some retrospective studies have been conducted to assess
CPE effects [85, 86], finding negative effects on HAD and
advanced HIV-related neurological conditions. Prospective
observational studies produce effects that are only indica-
tive, as there is a large amount of bias that demands vali-
dation in RCTs [87]. However, the risk of bias is highest in
retrospective studies as the treatment effect is not con-
trolled while the definition of the outcome of interest is
historical and out-dated in the case of HAND. As explained
above, there are unfortunately sub-optimal methods for
defining HAND. Therefore, using a poor historical defini-
tion that varies between countries and fails to document
neuropsychological confounds is one of the worst-case
scenarios. Because of this and contrary to the dedicated
editorial [88], the findings of Caniglia et al. [85], recently
published in Neurology, are less than convincing. Selection
[89] and ART channeling bias [90] could explain the entire
study results as these are impossible to quantify or control
using post hoc adjustments. The large sample size very
likely yielded a large bias effect so that the CPE absolute
risk was in fact unclear. For example, when Zidovudine
(AZT) and nevirapine were the unique primary treatment in
rich economy countries, doctors were well aware that
cognitive improvements had only been demonstrated for
those agents [91]. The same thing happened for abacavir,
albeit transitionally as issues of cardio-vascular toxicity
had not reached the forefront yet [92]. Moreover, as judi-
ciously noted by researchers and clinicians in limited-re-
sources settings [90], AZT and nevirapine currently form
part of the first-line treatment in low-income countries.
Thus, the message of the Caniglia et al. study is confusing
for countries with the highest HIV burden. This example
highlights the ongoing need for well-designed RCTs on
cART and brain functions including low-income countries,
where observational treatment studies and a few RCTs
have been successfully conducted (e.g., see [93–95] and the
review [96] for a more global perspective). Altogether,
retrospective studies must not be conducted to assess
treatment effects on brain functions, especially now that we
understand HAND as a spectrum that has shifted towards
milder forms, which need to be adequately represented in
RCTs.
One RCT [97] that has been conducted found no evi-
dence for superior neurocognitive functioning in the high-
CPE (n = 23) versus low-CPE (n = 19) arms. However,
the study lacked statistical power as accrual was incom-
plete. The authors also noted several differences in baseline
characteristics between the treatment arms than could have
influenced neurocognitive performance (i.e., the high-CPE
arm had numerically lower mean CD4, higher rates of
hepatitis C co-infection, and showed a trend for poorer
plasma virological suppression, potentially due to
antiretroviral instability prior to enrolment). Finally, the
patients were followed up at 16 weeks, but there is evi-
dence that recovery from a HAND episode takes at least
42 weeks [98]. The trial demonstrates that accrual strate-
gies have to be well-thought-out, that use of adaptive
randomization is highly preferable, and that a larger trial
including sites in low–medium-income countries is needed.
Nevertheless, we propose here that a fundamental collab-
orative reworking of CPE itself is needed.
Indeed, some researchers have recently started to ask
important questions on reconceptualizing CPE [99] fol-
lowing propositions from Brew and colleagues in 2009
[77]. One study suggested that cART genotypic suscepti-
bility should be considered, validating that a CPE score
accounting for this factor is associated with superior neu-
rocognitive performance in a fairly large HIV? sample
[100]. Other findings relating to the potential toxicity of
some ART as a factor in HAND neuropathogenesis suggest
that a toxicity weighting should also be considered in the
CPE score [101]. For example, this is particularly relevant
for efavirenz, but results are not settled (see next section).
Other factors that will need to be considered include
putative brain mitochondrial toxicity (which remains
understudied) along with peripheral toxicities (i.e., renal,
cardiovascular, oxidative stress) that can lead to/worsen
neurocognitive deficits in chronic HIV? persons.
On the other hand, the cumulatively demonstrated
capacity of high-CPE regimens to reduce CSF viral load
more swiftly and/or to a greater extent than low-CPE
regimens should not be discounted [78]. Assuming a direct
linear effect between CPE and neurocognitive functioning
is probably incorrect. It is more likely that several
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mediators including speed of viral decay in the CNS
influence the extent of neurocognitive recovery, which
itself depends on baseline level of impairment. This
interpretation was strongly supported by our 2009 CPE
study [98], albeit a non-RCT. This scenario has important
implications for a chronic disease—early initiation of high-
CPE regimens in patients at risk of HAND could reduce the
likelihood (see first study [102] in next section) and
severity of relapse. Finally, the reasoning that a group of
antiretrovirals are better for brain functioning should not be
abandoned as a potential rationale, but rather construc-
tively and empirically improved. Additional supportive
evidence is emerging from relatively novel single ART
agents, as we will review below. This opinion is shared in
the ‘‘treatment for HAND’’ section of a review on Con-
ference on Retroviruses and Opportunistic Infections
(CROI) 2015 findings [103].
5 Specific Agents or Classes of Agents
5.1 Efavirenz
There is an excellent review dedicated to efavirenz, neu-
rocognitive functions and neuropsychiatric symptoms
[104], and more recently, a systematic review calling for
‘‘large RCTs to determine if the neuronal toxicity induced
by efavirenz results in clinically significant neurological
impairment’’ [105]. Most recent non-RCT results have
been presented at CROI 2015 and reviewed by Spudich and
Ances [103], indicating yet more conflicting effects of the
drug. Therefore, we focus on recent findings only in RCTs
and a novel finding in an animal model study. Between
2010 and 2015, one RCT has been conducted and fully
published [106]; another RCT was conducted and pre-
sented at CROI 2015.
The first pilot RCT was conducted in therapy-naı¨ve
patients defined as ‘‘neuro-asymptomatic,’’ probably on
clinical grounds, and included 28 participants randomized to
tenofovir/emtricitabine with efavirenz (arm 1), atazanavir/
ritonavir (arm 2) or ATZ/abacavir (arm 3). Importantly, it
formed a sub-study of a larger trial [107], which showed that
efavirenz and ritonavir-boosted atazanavir arms were
equivalent in viral suppression and safety. The sub-study
design probably explains why a more comprehensive
baseline neuropsychological assessment was not included a
priori. Improvement was noted across the board, but the
efavirenz-containing arm showed the least improvement on
the total composite CogState score and the processing speed
cognitive domain. Without knowing patients’ baseline level
of neurocognitive functioning, it is very difficult to interpret
the results. This study clearly illustrates the need to deter-
mine HAND at baseline since trajectories for improvement
or decline depend more strongly on this than any treatment
effects. In other words, detection of any specific antiretro-
viral effect requires an RCT to be powered above and
beyond the main cART effect as well as the practice effect.
Also, given the importance of baseline performance in
predicting HAND neurocognitive trajectories, it is advisable
for adaptive randomization techniques to be implemented in
future trials to ensure equal representation of the HAND
spectrum across treatment arms. Another criticism of the
study is that improvement was detected despite the patients
being labeled ‘‘neuro-asymptomatic,’’ potentially indicating
that some had ANI (perhaps even MND), while others were
cognitively normal. Genuine cognitive improvement would
not be expected in neurologically intact persons, so the
‘‘improvement’’ may solely reflect practice effects. How-
ever, we cannot be certain that was the case for this partic-
ular study [108]. The study ran for 48 weeks, with a medium
time point at 24 weeks; the authors noted improvement over
this period in different cognitive abilities. The study indi-
rectly confirms that cART RCTs should be based on a
medium- to long-term timeline (i.e., at least 52 weeks) to
capture complex repair processes within the brain as well as
normal fluctuations on repeated testing. The study also used
CogState to assess neurocognitive change. While the test
batteries developed for CogState were designed to minimize
practice effects, this confound cannot be eliminated and is
particularly pronounced in some cognitive domains (e.g.,
executive functioning) where the authors noted improve-
ment at the longer time point. Thus, caution is warranted
when interpreting improvement in executive functioning (or
any functions for that matter) in terms of ART effects,
especially when no attempt to control for potential practice
effects has been made. Unfortunately, though, there is still
ongoing debate as to the optimal approach for practice effect
‘‘extraction’’ in RCTs. Further, consultation with biostatis-
ticians and neuropsychologists is advised. This trial also
illustrates another problem we have already outlined above,
namely that if assessments lack sufficient comprehensive-
ness, improvement in some cognitive domains may be
missed, as different neuropsychological measures behave
differently on repeated testing, reflecting both test idiosyn-
crasies and specific brain functions.
The second RCT was presented orally at CROI 2015
[102] and is yet to be published at the time of writing. We
include it here because it was based on the largest ever
sample for an HIV treatment RCT in the cART era and
aimed to assess cART prevention of HAND. HIV? ther-
apy-naı¨ve adults (N = 250) were randomized to either
AZT-lamivudine-nevirapine or tenofovir-lamivudine-efa-
virenz. Comprehensive neuropsychological assessment
determined that all were neurocognitively normal as per
Frascati criteria using the GDS method. This is an impor-
tant point given the primary study aim to assess incident
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neurocognitive impairment; if the authors had used a short
battery (adopting the rationale that some domains should
not be tested) or determined neurological status based on
clinical grounds, reliability in the determination of this
outcome would have been substantially weakened. Using
standard regression-based change scores derived from a
demographically comparable control group (methods that
control for practice effects and regression towards the
mean but add historical bias in an RCT), the authors found
incident impairment at 96 weeks was greater in the teno-
fovir-lamivudine-efavirenz arm than in the other arm.
However, a higher proportion of adverse events were noted
in the AZT-lamivudine-nevirapine arm. These results
support the rationale that not all antiretroviral regimens are
equivalent for preventing HAND. CNS and peripheral
toxicity cannot be excluded as a potential confounding
factor while viral suppression was equivalent between
regimens. In the anticipated publication, it would be
important for the authors to detail the trajectories of indi-
viduals according to their baseline performance and whe-
ther particular neurocognitive functions were associated
with decline in the efavirenz arm. Nonetheless, the study
represents a strong proof-of-concept for larger
implementation.
Decloedt and Maartens [105] note that ‘‘several mech-
anisms exist to explain the observed efavirenz neurotoxi-
city, including altered calcium hemostasis, decreases in
brain creatine kinase, mitochondrial damage, increases in
brain proinflammatory cytokines and involvement of the
cannabinoid system.’’ Moreover, another mechanism has
recently been proposed which could have important
implications for aging HIV? persons. Indeed, Brown et al.
[109] have found in a murine model (murine N2a cells
transfected with the human ‘‘Swedish’’ mutant form of
amyloid precursor protein) that efavirenz promotes b-sec-
retase expression and increased Ab1-40,42 via oxidative
stress and reduced microglial phagocytosis. While pre-
liminary, this finding suggests that some efavirenz effects
could be long term, potentially explaining the conflicting
research findings to date relating to the drug [104].
5.2 Fusion/Entry Inhibitor (Maraviroc)
Intensification Studies
Maraviroc has good CSF penetration as well as anti-neu-
roinflammatory properties [110–113]. Preliminary data
supporting a potential neurocognitive benefit of a maravi-
roc-intensified regimen were reported in a sub-analysis of a
recent single-arm, open-label pilot study. A small subset
(n = 6) of HIV? participants with mild to moderate global
neurocognitive impairment improved over 24 weeks [114].
In a slightly larger prospective, double observer-blinded,
open-label pilot RCT [115] (all established HAND cases,
virally suppressed in plasma and CSF: n = 9 maraviroc-
intensified arm and n = 5 existing regimen control arm;
assessed at baseline and 6 and 12 months on a five-cog-
nitive domain battery), we found medium to large effect
sizes favoring improved global neurocognitive perfor-
mance in the maraviroc-intensified arm over time (after
correcting for practice effects and using adaptive random-
ization for HIV factors and mild co-morbidities). Both
studies support the need for larger RCTs.
5.3 Protease Inhibitors
Recently, several European observational studies have
investigated whether protease inhibitor (PI) monother-
apy/dual therapy differs from more traditional triple ther-
apy in terms of neurocognitive outcomes [116–118] given
they could be considered as alternative regimens (lower
cost, less toxicity) in patients with chronic HIV infection
who are otherwise well-controlled if they have sufficiently
high genetic barriers to resistance [119]. For example, the
largest observational cross-sectional study (N = 191) [117]
assessing boosted lopinavir or darunavir as monotherapy
versus triple ART found the mild to moderate neurocog-
nitive impairment rate did not differ in otherwise low-
confound and well-controlled patients. This finding was
subsequently extended in a prospective observational
cohort [120]. However, well-powered longitudinal RCTs
are still needed to further determine the validity of these
results. On the same topic, Spudich and Ances [103]
highlighted the findings of Caramatti et al. [121], who
showed in a multicenter, randomized, open-label trial that
atazanavir/ritonavir (ATV/r) monotherapy (n = 28) and
ATV/r triple therapy (n = 37) yielded similar neurocog-
nitive improvement over time. Specifically, HAND
prevalence at baseline was 66 % and this dropped to 37 %
after 96 weeks, with no between-group differences. These
results lend support to an earlier RCT (N = 200) [93],
which similarly found no differences in neurocognitive
impairment rates at baseline and 48 weeks between
patients randomized to second-line lopinavir/ritonavir-
based triple therapy versus lopinavir/ritonavir monother-
apy, albeit using a reduced number of neurocognitive tests.
This alternative treatment could be used in some well-
controlled chronic HIV? patients if it is found to not be
associated with HAND incidence over the long term.
However, larger RCTs are still needed to fully determine
its safety impact on the CNS, particularly the risk of CSF
viral escape.
5.4 Integrase Inhibitors
The integrase inhibitor raltegravir demonstrates reasonable
CNS penetration [122, 123], albeit with large inter-
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individual variability [124]. Raltegravir is widely used in
rich-economy countries, mainly as part of a second-line
treatment. Raltegravir-intensification studies focusing on
neurocognitive effects are unlikely to eventuate because of
its widespread existing use in contributing to high CPE
regimen in chronically HIV? patients [17]. Another
promising agent in this regard is dolutegravir, which also
shows decent CSF concentration [125]. Larger RCTs
dedicated specifically to neurocognitive changes are nee-
ded for these agents, potentially as part of a modified CPE
score given their widespread clinical use to date.
6 When Should cART be Initiated to Avoid
Incident HAND?
At the time of writing, results of the large RCT Strategic
Timing of Antiretroviral Treatment (START) had just been
announced by National Institutes of Health (NIH) [126].
This study is arguably the RCT needed to settle the debate
over benefits versus adverse effects of early cART. The
main study results provide a clear conclusion: ‘‘the initia-
tion of antiretroviral therapy in HIV-positive adults with a
CD4 ? count of more than 500 cells per cubic millimeter
provided net benefits over starting such therapy in patients
after the CD4? count had declined to 350 cells per cubic
millimeter’’ [127]. Importantly, with more HIV? patients
starting treatment earlier, the clinical prevalence of HAND
is likely to shift even further towards milder forms,
emphasizing the need for early detection and at least passive
monitoring using screening tools validated for longitudinal
assessment. However, early cART is not without its long-
term consequences in terms of cumulative toxicity and
potential neuro/cardiotoxicity, as well as variable adherence
level in different HIV populations. These will need to be
carefully considered moving forward. Finally, the practical
and financial complexities of an early cART implementa-
tion program have already been noted, especially at an
international level. On the positive side, there is a strong
argument for early ART as an indirect mode for reducing
new HIV infection [127]. The START study included a
neurology sub-study, for which the results are pending.
7 Future Research Directions
While neuropsychological assessment remains a very use-
ful method to assess current neurocognitive functioning
and determine the clinical relevance of neurocognitive
impairment, HIV treatment studies should start to also
include neuroimaging outcomes, when possible, in order to
enhance the neurobiological validity and interpretation of
HIV treatment effects. Not all neuroimaging outcomes are
valuable for ART effects on brain functions, given the
subtle nature of change observed. Structural Magnetic
Resonance Imaging (MRI) methods are probably insensi-
tive as brain macro-structural changes (e.g., atrophy) are
unlikely to be directly affected by treatment effects (at least
over the time period that most RCTs are conducted).
However, one particular method should be strongly con-
sidered as it measures the chemical mechanisms that
putatively underlie treatment effects: magnetic resonance
spectroscopy (MRS). Indeed, this in vivo imaging is quick,
non-invasive and can provide key information regarding
neurochemical abnormalities associated with HIV or
treatment effects [128] during/prior to any neurocognitive
evidence of HAND and even during primary HIV infection
[129], as well as potential ART-related neurotoxicity [130],
which needs to start to be seriously considered in longi-
tudinal research. As with neuropsychological data, careful
characterization of the baseline metabolite profile is very
important for any RCT [131]. Also, demographic effects
ought to be characterized. Determination of other technical
conditions should ideally involve MRS experts, include
voxel size/positioning depending on the regions of interest,
type of signal reference, sequences for absolute/relative
concentrations, signal fitting and reliability, various signal
corrections as well as the timeline of measurements [132].
Finally, because MRS is relatively expensive (though
industry-sponsored studies will likely afford the cost) and/
or not all countries have access to MRI scanners and MRS
expertise, not all RCTs may be able to include this method
in the near future. However, recent technological
improvement makes the acquisition of spectroscopic data
quicker than ever; additionally, there is already a precedent
for collaborative MRS neuroHIV treatment studies
between countries with a participant cohort recruited in a
low–middle-income country, demonstrating its future
potential in such research [133].
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